Cognition enhancing compounds and compositions, methods of making, and methods of treating
The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine receptors, and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives, compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.
1. A method for treating a disorder in an animal having said disorder, comprising administering to said animal an effective amount of a compound of Formula XI, a stereoisomer thereof or a pharmaceutically acceptable salt of said compound or stereoisomer, wherein the compound has the structure:
wherein
X is O or S;
R 1 is NH 2 , a C 1-6 alkyl group or a C 3-6 cycloalkyl group, wherein the alkyl or cycloalkyl groups are optionally substituted with 1 or more Deuterium (“D”);
R 2a , R 2b , R 4a , R 4b , R 5 , R 6a , and R 6b are independently selected from H or D; and
R 3 is H, D or an amino-protecting group; and
wherein the disorder is selected from the group consisting of presenile dementia, senile dementia, Parkinson's disease with dementia, Down's syndrome, Huntington's disease, tardive dyskinesia, hyperkinesia, mania, Tourette syndrome, Alzheimer's disease, cognitive impairment, Mild Cognitive Impairment, frontotemporal dementia, and dementia with Lewy bodies.
2. The method of claim 1 , wherein the disorder is selected from the group consisting of presenile dementia, senile dementia, Parkinson's disease with dementia, Down's syndrome, Huntington's disease, tardive dyskinesia, hyperkinesia, mania, Tourette syndrome and Alzheimer's disease.
3. A method according to claim 1 , wherein the disorder is selected from the group consisting of cognitive impairment, Mild Cognitive Impairment, frontotemporal dementia, dementia with Lewy bodies, presenile dementia, senile dementia, Down's syndrome, Huntington's disease, tardive dyskinesia, hyperkinesia, mania, Tourette syndrome and Alzheimer's disease.
4. A method of treating psychosis in a subject, comprising administering to a subject suffering from psychosis, a therapeutically effective amount of a compound of Formula XI, a stereoisomer thereof or a pharmaceutically acceptable salt of said compound or stereoisomer, wherein the compound has the structure:
wherein
X is O or S;
R 1 is NH 2 , a C 1-6 alkyl group or a C 3-6 cycloalkyl group, wherein the alkyl or cycloalkyl groups are optionally substituted with 1 or more Deuterium (“D”);
R 2a , R 2b , R 4a , R 4b , R 5 , R 6a , and R 6b are independently selected from H or D; and
R 3 is H, D or an amino-protecting group.
5. The method of claim 4 , wherein the psychosis accompanies or results from schizophrenia.
6. The method of claim 4 , wherein the psychosis accompanies or results from Alzheimer's disease.
7. A method for enhancing cognition in an animal, comprising administering to said animal a compound of Formula XI, a stereoisomer thereof or a pharmaceutically acceptable salt of said compound or stereoisomer, wherein the compound has the structure:
wherein
X is O or S;
R 1 is NH 2 , a C 1-6 alkyl group or a C 3-6 cycloalkyl group, wherein the alkyl or cycloalkyl groups are optionally substituted with 1 or more Deuterium (“D”);
R 2a , R 2b , R 4a , R 4b , R 5 , R 6a , and R 6b are independently selected from H or D; and
R 3 is H, D or an amino-protecting group.
8. The method of claim 1 , comprising administering to said animal an effective amount of the compound
a stereoisomer thereof or a pharmaceutically acceptable salt of said compound or stereoisomer.
9. The method of claim 8 , wherein the disorder is Alzheimer's disease.
10. The method of claim 1 , comprising administering to said animal an effective amount of the compound
a stereoisomer thereof or a pharmaceutically acceptable salt of said compound or stereoisomer.
11. The method of claim 10 , wherein the disorder is Alzheimer's disease.
12. The method of claim 4 , comprising administering to said animal an effective amount of the compound
a stereoisomer thereof or a pharmaceutically acceptable salt of said compound or stereoisomer.
13. The method of claim 4 , comprising administering to said animal an effective amount of the compound
a stereoisomer thereof or a pharmaceutically acceptable salt of said compound or stereoisomer.
14. The method of claim 5 , comprising administering to said animal an effective amount of the compound
a stereoisomer thereof or a pharmaceutically acceptable salt of said compound or stereoisomer.
15. The method of claim 5 , comprising administering to said animal an effective amount of the compound
a stereoisomer thereof or a pharmaceutically acceptable salt of said compound or stereoisomer.
16. The method of claim 7 , comprising administering to said animal an effective amount of the compound
a stereoisomer thereof or a pharmaceutically acceptable salt of said compound or stereoisomer.
17. The method of claim 7 , comprising administering to said animal an effective amount of the compound
a stereoisomer thereof or a pharmaceutically acceptable salt of said compound or stereoisomer.
18. The method of claim 1 , wherein X is O, and the disorder is Alzheimer's disease.
19. The method of claim 4 , wherein X is O.
20. The method of claim 7 , wherein X is O.